2019
DOI: 10.1172/jci.insight.128528
|View full text |Cite
|
Sign up to set email alerts
|

Imaging mass spectrometry reveals heterogeneity of proliferation and metabolism in atherosclerosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
36
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 23 publications
(37 citation statements)
references
References 23 publications
1
36
0
Order By: Relevance
“…In order to assess the degree of tumor metabolic heterogeneity in vivo , we utilized MIMS to track labeled metabolic substrates, using a cocktail consisting of 2 H-glucose, 15 N-glutamine, and BrdU administered over 24 h to murine tumor models ( Figure 2 A). Our choice of label dose reflected our goal to achieve sufficiently high labeling in order to facilitate label detection within a reasonable amount of time and prior experience with amino acid and glucose metabolic labeling in other physiological or pathophysiological contexts ( Guillermier et al., 2017b , 2019 ; Zhang et al., 2012 ). We first labeled an Nf1 +/− ;Tp53 +/− mouse model of malignant peripheral nerve sheath tumor (MPNST), incidentally finding a second intra-abdominal histiosarcoma, which in both tumor types is caused by a stochastic loss of wild-type Nf1 and Tp53 alleles.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In order to assess the degree of tumor metabolic heterogeneity in vivo , we utilized MIMS to track labeled metabolic substrates, using a cocktail consisting of 2 H-glucose, 15 N-glutamine, and BrdU administered over 24 h to murine tumor models ( Figure 2 A). Our choice of label dose reflected our goal to achieve sufficiently high labeling in order to facilitate label detection within a reasonable amount of time and prior experience with amino acid and glucose metabolic labeling in other physiological or pathophysiological contexts ( Guillermier et al., 2017b , 2019 ; Zhang et al., 2012 ). We first labeled an Nf1 +/− ;Tp53 +/− mouse model of malignant peripheral nerve sheath tumor (MPNST), incidentally finding a second intra-abdominal histiosarcoma, which in both tumor types is caused by a stochastic loss of wild-type Nf1 and Tp53 alleles.…”
Section: Resultsmentioning
confidence: 99%
“…Prior applications of MIMS to non-cancerous tissues has provided a framework to quantify stable isotope-tagged glucose, amino acids, and precursors of nucleic acid synthesis in a multiplexed fashion ( Guillermier et al., 2017b , 2019 ; Steinhauser et al., 2012 ; Zhang et al., 2012 ). We reasoned that MIMS could also enable quantitative measurement of substrate utilization in individual cancer cells, thereby enabling us to test the hypothesis that tumors exhibit metabolic heterogeneity at the level of individual cancer cells.…”
Section: Introductionmentioning
confidence: 99%
“…However, the underlying molecular and metabolic mechanisms remain unknown. A recent study using multi-isotope imaging mass spectrometry found that plaque proliferating cells used preferentially glucose in comparison to neighboring non-proliferating cells [21]. Surprisingly, foamy cells were highly glucose consuming and this was correlated with increased proliferation [21].…”
Section: Immune Cell Diversity In Atherosclerotic Plaquementioning
confidence: 99%
“…Nevertheless, recent studies have demonstrated the feasibility of different techniques for profiling the metabolome at the single-cell level from both cell cultures [67,68] and freshly resected tissues [69]. Among these techniques, mass spectrometry imaging (MSI) spatial metabolomics [70] is perhaps the most widely applicable, with the proven ability to characterize both metabolite levels and isotopic-labeling patterns at subcellular (and even suborganelle) resolutions [71]. The current caveat of MSI-based approaches is a necessary tradeoff between spatial resolution, metabolite coverage, and sensitivity.…”
Section: Box 3 Interpreting In Vivo Tracer Measurements (1): Pathwaymentioning
confidence: 99%